You are here: Home » Reuters » News
Business Standard

Takeda CEO prescribes surgical R&D cuts after $62 billion Shire deal

Reuters  |  LONDON 

By Ben HirschlerLONDON (Reuters) - For Christophe Weber, the boss of Japan's Takeda Pharmaceutical, securing a $62 billion deal last week to buy drugmaker Shire at the fifth time of asking was the easy bit.Now he has to steer what will be one of the world's most indebted drugmakers through the big spending cuts needed to make the financial sums work, without destroying the lifeblood of future innovation.At the same time he must win shareholders' support for the largest-ever overseas purchase by a Japanese company - something he told Reuters could be helped by bringing in one or more ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Thu, May 17 2018. 18:02 IST